Young-Hwan Jung

Title: Young-Hwan Jung: Innovator in P2Y Receptor Antagonists

Introduction

Young-Hwan Jung is a notable inventor based in Rockville, MD (US). He has made significant contributions to the field of pharmacology, particularly in the development of compounds that target P2Y receptors. His work is crucial for advancing treatments for various inflammatory diseases.

Latest Patents

Young-Hwan Jung holds a patent for "Heterocyclic P2Y receptor antagonists." This patent discloses compounds of formulas (I)-(IX) that are designed to treat or prevent diseases responsive to antagonism of a P2YR receptor agonist in mammals. The compounds are particularly useful in treating inflammatory conditions such as asthma, cystic fibrosis, and sterile inflammation of the kidney. He has 1 patent to his name.

Career Highlights

Young-Hwan Jung is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His role at this prestigious institution allows him to engage in cutting-edge research that has the potential to impact public health significantly.

Collaborations

Throughout his career, Young-Hwan Jung has collaborated with esteemed colleagues, including Kenneth Alan Jacobson and Jinha Yu. These collaborations enhance the research efforts and contribute to the development of innovative therapeutic solutions.

Conclusion

Young-Hwan Jung's work in the field of P2Y receptor antagonists exemplifies the importance of innovation in medical research. His contributions are paving the way for new treatments that can improve the quality of life for individuals suffering from inflammatory diseases.